SUSTAIN-6: The Landmark Trial That Proved Semaglutide Protects the Heart
Weekly semaglutide reduced major cardiovascular events by 26% in high-risk type 2 diabetes patients over 2 years, though it also increased retinopathy complications.
Quick Facts
What This Study Found
In the landmark SUSTAIN-6 trial, weekly semaglutide reduced the rate of major cardiovascular events (cardiovascular death, nonfatal heart attack, or nonfatal stroke) by 26% compared to placebo in patients with type 2 diabetes at high cardiovascular risk (hazard ratio 0.74; 95% CI 0.58–0.95; P<0.001 for noninferiority). The composite primary endpoint occurred in 6.6% of semaglutide patients versus 8.9% of placebo patients over 104 weeks.
Nonfatal stroke was reduced by 39% (HR 0.61; P=0.04) and nonfatal heart attack by 26% (HR 0.74; P=0.12, not statistically significant). Rates of new or worsening kidney disease were also lower with semaglutide. However, the trial flagged an unexpected safety signal: retinopathy complications were significantly higher with semaglutide (HR 1.76; P=0.02), a finding that required further investigation.
Key Numbers
How They Did This
Double-blind, randomized, placebo-controlled trial (SUSTAIN-6). 3,297 patients with type 2 diabetes on standard care were randomized to receive once-weekly semaglutide (0.5 mg or 1.0 mg) or placebo for 104 weeks. 83% of patients had established cardiovascular disease, chronic kidney disease, or both. The primary composite endpoint was the first occurrence of cardiovascular death, nonfatal MI, or nonfatal stroke.
Why This Research Matters
SUSTAIN-6 was a watershed moment for GLP-1 drugs. It was designed simply to prove semaglutide wasn't harmful to the heart (as required by FDA), but instead showed it was actively protective — reducing heart attacks and strokes by 26% overall. This transformed semaglutide from a diabetes drug into a cardiovascular medication and paved the way for its massive commercial success. The trial also revealed the retinopathy signal that would become an important monitoring point for clinicians prescribing semaglutide.
The Bigger Picture
SUSTAIN-6 was part of a series of cardiovascular outcomes trials that the FDA required for all new diabetes drugs after safety concerns with other classes. What made SUSTAIN-6 exceptional was that it went beyond proving safety — it showed genuine cardiovascular benefit. This trial, combined with similar results from liraglutide's LEADER trial, fundamentally changed how GLP-1 drugs are viewed: they're now considered cardiovascular drugs that also happen to lower blood sugar and cause weight loss. The SELECT trial later extended cardiovascular benefits to non-diabetic obese patients.
What This Study Doesn't Tell Us
The trial was designed as a noninferiority study, not a superiority study — it was powered to show semaglutide wasn't worse than placebo, not necessarily that it was better. The significant increase in retinopathy complications raised safety concerns. Cardiovascular death rates were not significantly different between groups. The study population was high-risk diabetes patients, so results may not generalize to all semaglutide users (e.g., those taking it purely for weight loss without diabetes).
Questions This Raises
- ?Do semaglutide's cardiovascular benefits extend to people without diabetes who take it for weight loss?
- ?What causes the increase in retinopathy complications and can it be mitigated with slower dose titration?
- ?Are the cardiovascular benefits driven by weight loss, direct vascular effects, or both?
Trust & Context
- Key Stat:
- 26% reduction in cardiovascular events Semaglutide cut the combined rate of cardiovascular death, heart attack, and stroke by 26% versus placebo over 2 years in 3,297 high-risk diabetes patients.
- Evidence Grade:
- This is a large, double-blind, randomized controlled trial published in the New England Journal of Medicine — the gold standard for clinical evidence. The study had adequate power and duration, though it was designed for noninferiority rather than superiority.
- Study Age:
- Published in 2016, SUSTAIN-6 is a foundational trial for semaglutide. Its cardiovascular findings have since been reinforced by additional trials including SELECT (2023) and remain central to semaglutide's clinical profile.
- Original Title:
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Published In:
- The New England journal of medicine, 375(19), 1834-1844 (2016)
- Authors:
- Marso, Steven P, Bain, Stephen C(9), Consoli, Agostino(4), Eliaschewitz, Freddy G, Jódar, Esteban, Leiter, Lawrence A, Lingvay, Ildiko, Rosenstock, Julio, Seufert, Jochen, Warren, Mark L, Woo, Vincent, Hansen, Oluf, Holst, Anders G, Pettersson, Jonas, Vilsbøll, Tina
- Database ID:
- RPEP-03041
Evidence Hierarchy
Frequently Asked Questions
Does semaglutide actually prevent heart attacks?
In this trial, semaglutide reduced the rate of nonfatal heart attacks by 26% and nonfatal strokes by 39% in high-risk type 2 diabetes patients. While no drug completely prevents heart attacks, semaglutide significantly lowered the risk compared to placebo over 2 years.
What is the retinopathy concern with semaglutide?
SUSTAIN-6 found that retinopathy complications (including vision-threatening conditions) were 76% more common with semaglutide than placebo. This is thought to be related to rapid blood sugar improvement, which can temporarily worsen diabetic eye disease. Patients with existing retinopathy should have their eyes monitored when starting semaglutide.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-03041APA
Marso, Steven P; Bain, Stephen C; Consoli, Agostino; Eliaschewitz, Freddy G; Jódar, Esteban; Leiter, Lawrence A; Lingvay, Ildiko; Rosenstock, Julio; Seufert, Jochen; Warren, Mark L; Woo, Vincent; Hansen, Oluf; Holst, Anders G; Pettersson, Jonas; Vilsbøll, Tina. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.. The New England journal of medicine, 375(19), 1834-1844.
MLA
Marso, Steven P, et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.." The New England journal of medicine, 2016.
RethinkPeptides
RethinkPeptides Research Database. "Semaglutide and Cardiovascular Outcomes in Patients with Typ..." RPEP-03041. Retrieved from https://rethinkpeptides.com/research/marso-2016-semaglutide-and-cardiovascular-outcomes
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.